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Preface	  
This paper is a Bachelor project and 6th semester project by students at Roskilde University (RUC). 
Its intended audience is readers with a background in molecular biology and molecular genetics at - 
at least - the Bachelor level. The paper concerns a research project on the regulation of the SOX9 
promoter in human colon cancer cells (Caco-2 line) under the influence of different transcription 
factors. Attached to the paper, a supplementary materials section gives more insight into the 
molecular mechanism of the different transcription factors in healthy intestinal epithelium and in 
colon cancer. In addition, the supplementary materials contain a more detailed description of the 
methods and the theory behind them. All laboratory work was conducted at the RUC laboratories 
under the supervision of Maiken Lise Marcker Espersen. 
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Part	  I:	  Resume	  
Colorectal cancer is currently the third most diagnosed cancer in males and second most in females, 
and the third leading cause of cancer deaths. Every year, more than a million individuals worldwide 
will develop colorectal cancer. It is known that colorectal carcinomas derive from the intestinal 
epithelium, which renews at a constant, high rate. Healthy intestinal epithelium depends on the 
proper functioning of developmental pathways. The small intestine and colon are very similar in 
morphology and development and scientists have used the much more extensively studied small 
intestinal cancer as a model for the development of colon cancer. However, recent research 
indicates that there may be some major differences in the differentiation of the multipotent stem 
cells by genes such as the SRY (sex determining region Y)-box 9 (SOX9). SOX9 helps maintain 
homeostasis in intestinal epithelium but its role in colon cancer is still debated; some studies 
describe it as an oncogene while others demonstrate a tumor suppressor role. Furthermore, SOX9 
overexpression is correlated with a poor prognosis in colorectal cancer. 
 
Table 1 shows the transcription factors used in the experiment and their interactions. 
 Location Function Colon Cancer Overexpression Underexpression Cofactors 
SOX9 Crypts (stem 
and Paneth 
cells) 
Maintain small intestine 
and colon morphology. 
Regulates proliferation. 
Suppress CDX2 
High levels Increased 
proliferation, 
decreases β-catenin-
TCF4 activity 
Increase in stem cell 
levels, fewer goblet 
cells, fewer Paneth 
cells 
Needs TCF4, 
suppresses 
CDX2 
TCF4 Small intestine: 
crypt-villus 
axis. 
Colon:  higher 
levels in the 
villi. 
Stem cell renewal. 
Tumor suppressor 
High levels Increased 
proliferation 
Lack of proliferative 
cells. Fully 
differentiated cells. 
Needs β-
catenin. 
Suppressed by 
HNF4-α 
CDX2 Villi Cell differentiation. 
Disrupts β-catenin-
TCF4 tumor suppressor 
Low levels. 
Almost absent. 
Important 
biomarker 
Induces transcription 
of anti-apoptotic 
factors 
Tumor development Inhibited by 
HNF4-α. 
Suppressed by 
SOX9. 
HNF4-
α 
Crypt-villus 
axis, except at 
very bottom of 
the crypts 
Maintenance of 
morphology, 
proliferation-
differentiation ratio 
Contradictory: loss 
of P1-HNF4-α 
protein 
Increased 
proliferation in the 
crypts 
Inability to develop 
crypts 
Inhibits TCF4 
and CDX2 
c-Jun + 
c-Fos 
Infrequent in 
colon 
Differentiation and 
apoptosis. Control of 
cell growth 
Elevated levels  Suppresses growth of 
human colon 
carcinoma cells 
Controlled by 
β-catenin-
TCF4 
Sp1  Regulation of cell 
proliferation, 
differentiation, 
apoptosis, drug 
resistance, metastasis 
High levels Increased 
proliferation 
Decreases tumor 
formation 
 
NF-kβ 
(p65, 
p552, 
p50) 
 Self-proliferation, 
regulating immune 
inflammatory response, 
regulation of apoptosis 
High levels  Decrease in tumor 
number, apoptosis 
 
	  
The aim of this study is to identify, from literature research, transcription factors candidates that 
play a role in signalling pathways and colon cancer development and potentially regulate SOX9 
promoter. The effects of different transcription factors on the expression of the SOX9 promoter will 
be compared to normal expression levels of SOX9 in Caco-2 cells, a line of human colon cancer 
cells. To validate their function and determine SOX9 promoter activity, a luciferase assay will be 
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conducted on transfected Caco-2 cells. The transcription factors used in the experiment are TCF4, 
CDX2, HNF4-α, c-Jun with c-Fos, SP1, p65 with p50, p65 with p52 and SOX9 (to test self-
regulation). 
 
Figure 1:  Structure of the small intestine and the colon. 
 
	  
Transcription	  Factors	  
SOX9 
SOX9 is a part of the HMG-box (high motility group) transcription factors and is necessary for 
committed cell differentiation. SOX9 plays a role in differentiation of adult stem cells in the small 
intestinal and colon epithelium. When SOX9 is not expressed in the small intestine cell 
differentiation does not occur, the number of stem cells is found to be higher-than-normal, and the 
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intestine crypts have altered morphology. Studies in mice have shown that Sox9 deficiency alone is 
not able to induce cancerous cells but overexpression of SOX9 in humans has been associated with 
development of colorectal cancer, together with several signalling pathways. SOX9 is expressed 
when Wnt signaling is active and because Wnt pathway is up-regulated in cancer cells, SOX9 gene 
is strongly expressed as well. In colon carcinoma cells, high expression of SOX9 has been identified 
in the same cells where β-catenin-TCF4 transcription factor complex was active, which suggests a 
correlation between SOX9 and TCF4.  
 
TCF4 
TCF4 is a transcription factor that suppresses transcription of genes from the Wnt pathway, 
including SOX9, but acts as an activator when it is bound by β-catenin. Furthermore, when the β-
catenin-TCF4 complex is not able to associate due to a TCF4 mutant that lacks β-catenin binding 
site, SOX9 is not expressed. This might further imply that SOX9 expression is driven by β-catenin-
TCF4 association, which suggests that SOX9 is a downstream target of Wnt signaling. 
In the colon, there are lower TCF4 levels in the proliferative cells from the crypts with increasing 
TCF4 levels towards the epithelium surface in the differentiated cells. The levels of TCF4 along the 
crypts act like a switch from proliferation to differentiation. Mice with one deleted Tcf4 allele 
lacked proliferative cells in the crypts and instead fully differentiated cells were observed. This 
implies that Tcf4 is vital in stem cell renewal and that higher association of β-catenin-Tcf4 complex 
in the small intestine and colon results in tumorigenesis. 
 
CDX2 
SOX9 represses CDX2, a tumor suppressor gene that regulates cell growth and differentiation in 
intestinal epithelium. Many studies have highlighted the tumor suppressor function of CDX2 
because it can reduce proliferation in some colon cancer and also because of its absence from tumor 
cells. However, CDX2 has also been correlated with a tumor inducing function in at least two 
studies.  
 
HNF4-α 
Hepatocyte nuclear factor 4 alpha (HNF4α) is a part of the nuclear receptor superfamily of ligand 
dependent transcription factors. HNF4α acts as a tumor suppressor in hepatocytes but its function in 
the small intestine and colon is not well understood. The absence of HNF4α in colon resulted in 
inability to develop crypts. It is not yet fully understood if HNF4a acts as an oncogene or a tumor 
suppressor. 
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Sp1 
The transcription factor specificity protein 1 (Sp1) plays a role in the development and progression 
of several types of cancers and it has been found to be expressed in 74% of colon cancer tissue. It 
has been found that Sp1 is overexpressed in colon cancer tissue.  
 
c-Jun and c-Fos: AP-1 
The transcription factor c-Jun plays an essential role in differentiation and apoptosis. c-Jun forms a 
complex with c-Fos resulting in the formation of Activator Protein-1 (AP-1). The AP-1 complex 
binds to promoter regions of DNA at AP-1 specific sites and enhance regions of target genes.  It is 
phosphorylated and activated by the JNK pathway. Increased activity of the JNK pathway has been 
found in human tumors.  
 
NF-κβ 
The nuclear factor-κβ, NF-κβ, has been found to be active in all cells. It has been shown that NF-κβ 
regulates a variety of genes involved in cell proliferation, tumorigenesis and metastasis in cancer 
and it is therefore an area of interest if it is involved in regulating SOX9 [Wang et al., 2009]. 
P65/P50 and P65/P52 are both dimers of the NF-κβ. 
 
Methods	  
In this experiment a DNA fragment containing the SOX9 promoter region was inserted into a 
cloning vector, pGL 4.10 [luc2], by digestion with HindIII restriction enzyme and amplification 
with polymerase chain reaction (PCR) to create a plasmid. The cloning vector contained a modified 
gene for luciferase, a firefly protein that produces light and can be used to measure the expression 
levels of SOX9 in the samples. To get the SOX9 promoter into the vector, the round vector is 
linearized by digestion with HindIII restriction enzyme. SOX9 was amplified using a touch down 
PCR and primers specific to the SOX9 promoter. The DNA produced in the PCR was then cloned 
into the linearized pGL 4.10 vector using a kit. The now-complete plasmid was purified and 
transformed into competent E. coli to further amplify the DNA. The E. coli were lysed to collect the 
plasmid and the purified plasmids were then transfected into Caco-2 human cancer cells. The clones 
contained different amounts of DNA inserts and are identified as 1:3 and 1:4 but are otherwise 
identical. The Caco-2 cells were transfected with transcription factors via centrifugation and 
treatment with polyethylenimine (PEI). Following incubation with the plasmids and transcription 
factors, the Caco-2 cells were lysed and the lysate was analyzed with a luciferase assay. 
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Results	  
The 1:3 and 1:4 samples were found to be comparable, with the exception of the CDX2 + HNF4-α, 
SP1, and p65 + p52 samples. 
 
Figures 2 & 3 show the results of the replicate clones. Samples that deviate significantly (α < 0.05) 
from controls - Caco-2 cells containing the pGL 4.10 [SOX9] vector - are indicated with an 
asterisk (*). Results that are highly significant are indicated by a double asterisk. 
 
Discussion	  
SOX9 
Our results show that SOX9 down-regulates expression of its own promoter. 
 
TCF4 
From our results, SOX9 promoter activity is not significantly affected when co-transfected with 
TCF4. However, SOX9 needs TCF4 to get expressed. This means that endogenous TCF4 levels are 
required to express SOX9, but higher levels of TCF4 do not influence SOX9 promoter behavior. 
 
CDX2 
SOX9 promoter activation in CDX2 samples did not deviate significantly from controls, contrary to 
our expectation of lowered SOX9 activation as a result of suppression of Wnt pathway. 
 
HNF4-α 
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HNF4α is known to repress the Wnt pathway. Our result show a tremendous increase in SOX9 
promoter activity, however. This might suggest that HNF4α directly binds the SOX9 promoter 
enhancing it despite the fact that it also acts to inhibit the Wnt pathway, which would affect SOX9 
expression negatively. 
 
Sp1 
To our knowledge no studies investigated the influence of Sp1 on the SOX9 promoter in intestinal 
or colon epithelium, however, it has been shown that Sp1 binds the SOX9 promoter a two sites in 
chondrocytes. In our study, Sp1 suppresses SOX9 promoter instead of enhancing its activity like in 
the chondrocytes. 
 
c-Jun and c-Fos: AP-1 
The protein c-Jun is the main factor in JNK pathway and it has been shown to directly regulate Wnt 
signalling which controls proliferation and SOX9 expression. c-Jun directly binds TCF4 gene and 
TCF4 protein is highly expressed in tumour cells that express c-Jun. Binding of c-Jun protein to the 
TCF4 promoter increases the expression of TCF4 and the Wnt pathway is strongly activated. Since 
Wnt pathway is up regulated in the presence of c-jun, SOX9 would be more expressed as well, 
however our experiment shows that SOX9 promoter activity is decreased when it is co-transfected 
with c-jun and c-fos. This might happen either because the dimer formed by c-Jun with c-Fos does 
not have such high affinity for TCF4 promoter compared to c-Jun alone, therefore Wnt pathway is 
not as active or because c-Jun and c-Fos dimer directly binds the SOX9 promoter and suppresses it. 
 
NF-κβ 
P65/P50-treated samples showed lowered expression of SOX9 while samples treated with P65/P52, 
the other NF-κβ dimer, showed much higher expression. 
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Part	  II:	  Article	  
Abstract	  
The purpose of this study was to investigate the regulation of SOX9 in colon cancer. 
Although SOX9 is significant in organ development and patterning, little is known about its 
function in colorectal cancer. Moreover, SOX9 regulation by transcription factors which have been 
found to play a role in colorectal cancer is almost non-existent, with the exception of some Wnt 
pathway components. Therefore, an investigation of the SOX9 promoter activity was conducted by 
transfecting Caco-2 cells with a pGL4.10 vector containing a luciferase gene under the control of 
the SOX9 promoter. Clones of the SOX9 plasmid from two different bacterial colonies were used 
separately in two sets of transfection. Sequence analysis of the two clones and alignment with the 
original promoter sequence showed no significant differences (data not shown). Additional co-
transfections contained other plasmids expressing transcription factors correlated with colon cancer: 
CDX2, TCF4, HNF4a, Sp-1, c-jun, c-fos, p65, p52, and p50. All samples were analyzed with a 
luciferase assay to determine the SOX9 promoter activity under the influence of the aforementioned 
transcription factors. The transcription factors P65 + P52, CDX2 + HNF4-α, and HNF4-α increase 
the promoter activity significantly, determined by a Student T-Test. P65 + P50, c-jun + c-fos, and 
SOX9 decrease the SOX9 promoter activity. In the one clone Sp1 appears to increase the promoter 
activity while in the other clone it decreased promoter activity. A 2-tailed independent sample 
Student T-Test was used to check for reproducibility between the two clones, and it was found that 
all samples except the CDX2 + HNF4-α, Sp1, and P65 + P52 were reproducible.  
 
Key Terms: Colorectal cancer, SOX9, Luciferase assay, Caco-2, pGL4.10, TCF4, SP1, CDX2, P65, 
P50, P52, c-jun, c-fos, HNF4-α, GFP. 	  
Abbreviations: AP-1: Activator Protein-1, CIMP: CpG island methylator phenotype, CRE: 
CREB response element GFP: green fluorescent protein, IAPs: apoptotic proteins, MAPK: 
mitogen-activated protein kinases, MSI: Microsatellite Instability, NF-𝜅𝛽: nuclear factor-kB, 
SOX9: SRY (sex determining region Y)-box 9, Sp1: specificity protein 1	  
	  
Introduction	  
Colorectal cancer is currently the third most diagnosed cancer in males and second most in 
females, and the third leading cause of cancer deaths [Jemal et al., 2011]. Every year, more than a 
million individuals worldwide will develop colorectal cancer [Cunningham et al., 2010]. The rates 
of the cancer increase with industrialization and urbanization, with a disease-specific mortality rate 
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of nearly 33% in the developed world [Cunningham et al., 2010; Labianca et al., 2010]. Risk 
factors are mainly older age and environmental causes which results in the buildup of genetic 
mutations and epigenetic changes, only about 5% of cases being inherited [Watson and Collins, 
2011]. Colorectal cancer is often divided into two groups. The subtype Microsatellite Instability 
(MSI) is located mainly in the ascending colon and is frequently associated with CpG island 
methylator phenotype (CIMP) and hyper-mutations. The second subtype is microsatellite-stable but 
chromosomally unstable. In this article we focus on MSI, which occur sporadically. 	  
Colorectal carcinomas derive from the colon epithelium, which renews at a constant, high 
rate. Healthy intestinal epithelium depends on the proper functioning of developmental pathways, 
especially the Wingless-related integration site (Wnt) pathway which is essential in preservation of 
adult stem cells and Paneth cells [van der Flier and Clevers, 2009]. The small intestine and colon 
are very similar in morphology and development. Therefore scientists have used the much more 
extensively studied small intestinal cancer as a model for the development of colon cancer. 
However, recent research indicates that there may be some major differences in the differentiation 
of the multipotent stem cells by genes such as the SRY (sex determining region Y)-box 9 (SOX9), 
found on chromosome 17 at the location chr17:70,117,161-70,122,560 (figure 1).  It has been 
shown that multiple transcriptional binding sites can be found in the promoter region of SOX9, 
which help regulate the gene.  It has been found that two CAAT boxes are located -100bp from the 
transcriptional start site, a CRE 1/2-site ( CRE is a palindromic sequence TGACGTGA which 
CREB can bind to, while the 1/2 -site consist of CGTGA) located at position -147, and two Sp-1 
like sites (Sp1-1 and Sp1-2) located adjacent to the CRE 1/2-site [Piera-Velazquez et al., 2007].  
Sites for ERBB2, SMAD family transcription factors, RNA polymerase II transcription factor II B, 
AP-1, POU domain transcription factors, E2F family transcription factors, TWIST subfamily 
transcription factor, NKX homeodomain factors, KLF transcription factors, and three NF-κβ 
binding sites are also found in the SOX9 promoter region [Lei Sun et al., 2013]. An earlier study of 
the mouse Sox9 promoter region also found  conserved transcription factor binding sites for GATA, 
CREB and two sites for GBF/NF-Y, and a possible SOX/SRY binding site [Kanai and Koopman, 
1999].	   
	  
Figure 1: SRY (sex determining region Y)-box 9 (SOX9), found on chromosome 17 at the 
location chr17:70,117,161-70,122,560. The gene has 3 exons. The promoter used in the experiment 
is found upstream of the first exon.  (UCSC Genome Browser) 
SOX9, encoded by the three exons of SOX9, helps maintain homeostasis in intestinal 
epithelium [Blache et al ., 2004] but its role in colon cancer is still debated; some studies describe it 
as an oncogene while others demonstrate a tumor suppressor role [Darido et al., 2009]. 
Furthermore, SOX9 overexpression is correlated with a poor prognosis in colorectal cancer [Lü et 
al., 2008]. SOX9 is a part of HMG-box (high motility group) transcription factors and is necessary 
for committed cell differentiation, as in chondrogenesis, male sex gonad or respiratory epithelium 
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development and melanocyte differentiation [Blache et al., 2004]. SOX9 also plays a role in 
differentiation of adult stem cells in the small intestinal and colon epithelium. It is mainly expressed 
in the intestinal stem and Paneth cells but its roles in these cells are not very well determined 
[Blache et al., 2004]. When SOX9 gene is not expressed, differentiation of Goblet cells is decreased 
and Paneth cells are completely absent [Bastide et al., 2007]. An increased number of stem cells 
was also observed which might suggest that SOX9 is needed to regulate the levels of proliferative 
and differentiated cells in the small intestine. Furthermore, when SOX9 is absent, abnormal cell 
proliferation was detected and the intestine crypts have altered shape. In addition, colon 
morphology was severely affected by folding and developing villi like areas [Bastide et al., 2007]. 
These changes in structure of the small intestine and colon suggest that SOX9 is important in 
maintaining their morphology. No carcinoma was detected in mice lacking SOX9 even after half a 
year, which means that SOX9 deficiency alone is not able to induce cancerous cells. This indicates 
that underexpression of SOX9 is not the cause of the cancer.   
On the other hand, overexpression of SOX9 has been associated with development of 
colorectal cancer together with several signaling pathways. Therefore, an investigation of the most 
important pathways was conducted in order to identify relevant transcription factors that disturb 
SOX9 normal function and were pointed out to play a role in the development of colon cancer.  The 
transcription factors selected for co-transfection with SOX9 were: TCF4 from the Wnt pathway, 
CDX2 and HNF4α, which are mainly expressed in the intestinal epithelium. Furthermore, 
transcription factors non-specific to the intestinal and colon epithelium but which were highly 
correlated with the initiation and development of cancer were co-transfected as well: SP1, c-jun and 
c-fos from the JNK pathway, p65/p59 and p65/p52 from NF- κβ. 
The aim of this study is to identify from literature research transcription factor candidates 
that play a role in signaling pathways and colon cancer development and potentially regulate the 
SOX9 promoter. The effects of different transcription factors on the expression of the SOX9 
promoter are compared to normal expression levels of SOX9 in Caco-2 cells, a line of human colon 
cancer cells. To validate their function and determine SOX9 promoter activity, a luciferase assay 
was conducted on transfected Caco-2 cells.  
	  
Materials	  and	  Methods	  	  
Making the plasmid 
The luciferase reporter vector, pGL4.10 [luc2] (Promega) was cut with HindIII restriction 
enzyme for linearization. Forward and reverse primers for the 703bp flanking region upstream of 
the SOX9 gene (Figure 2) were designed using UCSC Genome Browser, Primer3, and Clontech 
InFusion Primer Designer and were ordered from Eurofins Genomics. The SOX9 promoter was 
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amplified with a touch-down PCR on an Applied Biosystems Veriti 96-Well Thermal Cycler, 
following the program outlined in Table 2.	  
Table 2 shows the steps in the PCR program. Step 2 is repeated, with the temperature indicated by 
an asterisk decreasing by one degree Celsius for each cycle until 58°C. Step 3 is repeated 30 times.	  
Step 1	   Step 2	   Step 3	   Step 4	   Step 5	  
98°C	   98°C, 68°C*, 
72°C	  
98°C, 58°C, 72°C	   72°C	   8°C	  
30s	   10s, 1m, 2m	   10s, 1m, 2m	   7m	   ∞	  
PCR products were verified and purified in a 1% agarose gel using “E.Z.N.A Gel Extraction Kit” 
(Omega Bio-Tek) according to the manufacturer’s instructions for the spin protocol. The purified 
SOX9 DNA was cloned into the pGL 4.10 vector using Clontech Laboratories In-Fusion® HD 
Cloning Kit according to the manufacturer’s instructions, “Procedure for Spin-Column Purification 
of PCR Fragments”. 
Table 3: Forward and reverse primers for the SOX9 promoter.	  
OLIGO	   Tm	  
(Cᴼ)	  
GC%	   Primer	  Sequence	  
5'	  -­‐>	  3'	  
In-­‐fusion	  Primer	  Sequence	  	  
5'	  -­‐>	  3'	  
Resulting	  
Fragment	  
length	  	  
Forward	  
Primer	  
	  60.28	   50.00	   CGTAAACTCGGCTACGC
ATT	  
CTCGGCGGCCAAGCTTCGTAAA
CTCGGCTACGCATT	  
703	  bp	  
Reverse	  
Primer	  
59.69	   61.11	   CGGCGAGCACTTAGGA
AG	  
CCGGATTGCCAAGCTTCGGCGA
GCACTTAGGAAG	  
	  
Transformation of DNA in E. coli 
Complete plasmids, pGL 4.10 [luc2, SOX9], were transformed into competent E. coli cells 
for amplification using “One Shot MACH1” protocol (Invitrogen) according to the manufacturer’s 
instructions. Clones were created with different ratios of vector and PCR product inserts and are 
hereafter referred to as 1:3 (4 µl restriction enzyme, 2 µl vector, 6 µl PCR product, 8 µl H2O) or 1:4 
(4 µl restriction enzyme, 2 µl vector, 8 µl PCR product, 6 µl H2O). The clones are treated 
identically throughout the experiment. Overnight ampicillin-resistant colonies were selected and 
purified using the “Maxi” procedure of the “Nucleobond Xtra Plasmid Purification Kit” (Macherey-
Nagel) according to the manufacturer's instructions. The Maxi procedure was chosen to capture as 
much DNA as possible for the remaining steps of the experiment. To confirm the results, the clone 
was cut with HindIII restriction enzyme and run on a 1% agarose gel.  	  
 
Caco-2 cell culturing	  
Caco-2, human colon cancer cells, were grown in 75 cm2 VWR Tissue Culture Flasks 
(VWR International) at 37°C and 5% CO2. Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Lonza, cat. no. BE12-604F/U1) treated with 100 µg/ml streptomycin, 100 U/ml penicillin, and 
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10% foetal calf serum (Gibco) was used as growth media. Cell cultures were washed with sodium 
citrate to remove media, treated with trypsin (Gibco), and seeded into culture flasks when 70-90% 
confluent to prevent differentiation. Confluence was estimated by observation with a light 
microscope.	  
 
Transfection of Caco-2 cells 
80% confluent Caco-2 cells were trypsinized, counted under a light microscope, and seeded 
in four 24-well plates (Costar) at a concentration of 50.000 cells per well. Cells are incubated 
overnight at 37°C in fresh media. Following overnight incubation, the media is replaced with 1 ml 
fresh media. Duplicates for each transfection experiment for both the 1:3 and 1:4 clones, resulting 
in two 1:3 and two 1:4 samples for each transcription factor. The transcription factors and plasmids 
used in the transfection are TCF4 (Addgene plasmid # 16512), p65 (Addgene plasmid # 21966), 
p50 (Addgene plasmid # 21965), p52 (Addgene plasmid # 23289), CDX2 (pHIV-dTOMATO-
CDX2), HNF4-α, and SOX9 (Addgene plasmid # 36979). pGL 4.10 without SOX9 (Promega) is 
added to controls. CMV-lacZ is added for the assay. SK+ is added as filler DNA in some mixes to 
bring the DNA content to a high enough level. The c-Jun, c-Fos, and SP-1 transcription factors were 
kindly provided by Jørgen Olsen of the University of Copenhagen.  
Transcription factor plasmids were mixed with polyethyleneimine (PEI; 2 µM in 150 mM 
NaCl) in 1.5 ml Eppendorf tubes according to the scheme in the supplementary materials (tables 2 
& 3), vortexed thoroughly, and incubated at 20°C for one hour. 48 µl of the mixtures were added 
drop-by-drop to the Caco-2 wells. The plates were centrifuged at 1200 rpm for five minutes, then 
incubated for three hours at 37°C. Following incubation, all media was removed from the wells and 
replaced with 1 ml of DMEM.  
 
Luciferase Assay 
After media was removed from all 96 wells containing cells, 300µl of Dulbecco´s Phosphate 
Buffer Saline (PBS) was added to each well. After removing the PBS, 130µl of Tropix ® Lysis 
Solution (Applied Biosystems) combined with 6.5µl Dithiothreitol (DTT) (1M) was added to each 
well to lyse the cells. All plates were shaken by hand for five minutes and placed on ice. 10 µl of 
lysate from each well were transferred into a 96-well plate.	  
A Promega GloMax ® 96 Microplate Luminometer (Promega) was used to measure 
luciferase and β-galactosidase in the lysate according to the Applied Biosystems Dual-Light ® 
System (Applied Biosystems). To measure luciferase, the luminometer was loaded with the 96-well 
plate and two buffer solutions, buffers A and B. Buffer A contained 2.2 ml Dual-Light ® Reagent 
Buffer A (Applied Biosystems). Buffer B contained 4 ml Dual-Light ® Reagent Buffer B (Applied 
Biosystems) and 40 µl Tropix ® Galacton-Plus (Applied Biosystems) as a substrate for the 
reactions. During the assay each well was injected with 25 µl of buffer A and 100 µl of buffer B.	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Following the luciferase measurements, the samples incubated at 20°C for one hour, after 
which β-galactosidase activity was measured. β-galactosidase measurements were taken from the 
same 10 µl lysate samples as the luciferase assay and in the same 96-well plate. Buffer A was 
removed from the luminometer and replaced with 11.5 ml of Tropix ® Accelerator II (Applied 
Biosystems). 100 µl of Accelerator II was added to each well during the assay by the luminometer.	  
	  
Statistical	  Analysis	  
The results from the luciferase assay were analyzed using 2-tailed independent sample 
Students t-tests with α = 0.05 in Microsoft Excel. To make comparisons of the effects of different 
transcription factors on the expression of the SOX9 promoter a ratio of luciferase activity to β-
galactosidase activity was obtained for each sample. 
	  
Results	  
Several signaling pathways were investigated in order to identify possible transcription 
factors that might influence the SOX9 promoter. Plasmids of the most relevant candidates were then 
co-transfected into Caco-2 cells with the vector containing the SOX9 promoter and the reporter 
luciferase gene. The influence of the selected transcription factors on the SOX9 promoter activity 
was determined relative to the transfection of the vector with no transcription factors.  
Normalizing the results from the Dual-Light assay by dividing the results of the luciferase 
assay by the results of the β-galactosidase assay allows us to compare the effects of different 
transcription factors on the expression of the SOX9 promoter. Figures 2 and 3 show the normalized 
luciferase activity, calculated by luciferase measurement divided by the β-galactosidase activity of 
the 1:3 and 1:4 clones, respectively. It can be seen that the luciferase activity greatly increases when 
the transcription factors P65 + P52 and HNF4-α are present in both the 1:3 clones and 1:4 clones. 
When CDX2 and HNF4-α are combined we in 1:3 see the greatest decrease in activity compared to 
any other transcription factor, however in 1:4 we see an equal increase in activity as when HNF4-α 
is alone. At closer inspection of these differences it is apparent that the results of CDX2 and HNF4-
α in 1:3 should be disregarded due to having even lower values than the vector alone, and therefore 
there must have occurred an error in this sample. From this data Sp1 in 1:3 appears to increase the 
promoter activity slightly, while in the 1:4 clone it appears to decrease the promoter activity 
marginally. When taking the standard deviations into consideration, the transcription factors TCF4 
and CDX2 do not appear to have an effect on the luciferase activity. P65 + P50, c-jun + c-fos, and 
SOX9 results in a decrease in luciferase activity in both the 1:3 and 1:4 clone.  
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Figure 2: Normalized luciferase activity (luciferase/β-galactosidase) measured in the samples. 
pGL4.10 SOX9 (2.8 ng/µl) is used as the control for comparison of samples. * indicates a 
significant difference in activity from the control pGL4.10 SOX9 (2.8ng/ul). ** indicates a very 
great difference in activity from the control.  
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Figure 3: Normalized luciferase activity (luciferase/β-galactosidase) measured in the samples.* 
indicates a significant difference from the control pGL4.10 SOX9 (2.8ng/µl). ** indicates a very 
great difference in activity from the control. 	  
The relative expression ratio of the SOX9 with the expression factors versus the control, 
pGL4.10 with the SOX9 insert is calculated by dividing the average Luc/b-gal of the individual 
samples with the control. Figure 4 presents the relative expression ratio of the 1:3 clones. It is 
shown that the addition of P50 + P52 increases the expression of the SOX9 promoter by seven 
times, while the addition of the transcription factor HNF4-α increases the SOX9 promoter activity 
by nearly five times. P50 + P65, and c-jun + c-fos decreases the SOX9 promoter activity by 
approximately half.  Sp1 increases the SOX9 promoter activity slightly, while the SOX9 
transcription factor decreases its promoter activity slightly. From this analysis it appears that TCF4 
and CDX2 also increases the SOX9 promoter activity slightly.  Figure 5 shows the relative 
expression ratio of the 1:4 clone. P65 + P52, CDX2 + HNF4-α, and HNF4-α appears to increase the 
SOX9 promoter activity four times. In contrast, SOX9, c-jun +c-fos, and Sp1 decreases the SOX9 
promoter activity by nearly half. CDX2 and P65 + P50 appears to decrease the promoter activity 
slightly, while TCF4 increases the activity slightly.  
	  
Figure 4: Relative intensity of 1:3 clones compared to the control, pGL4.10 SOX9, with the 
baseline being one, increased promoter activity being above one, and decreased promoter activity 
being below one. 
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Figure 5: Relative intensity of 1:4 clones compared to the control, pGL4.10 SOX9, with the 
baseline being one, increased promoter activity being above one, and decreased promoter activity 
being below one. 
	  
Statistical	  Analysis	  
Luc/β-gal ratios from the 1:3 and 1:4 samples were compared using 2-tailed independent sample 
Students t-tests to check for reproducibility between the duplicates. The only significant differences 
found were between the CDX2 + HNF4-α samples, SP1 samples, and p65 + p52 samples. 
 
Table 2: results of a 2-tailed independent samples Students t-test comparing the 1:3 and 1:4 
samples in order to confirm that the results could be compared. Only the CDX2 + HNF4-α, SP1, 
and p65 + p52 show significant differences at the α = 0.05 level. 
Samples p 
PGL 4.10 [luc2, SOX9] 0.125 
TCF4 0.776 
CDX2 0.477 
p65 + p50 0.082 
p65  + p52 0.031 
SP1 0.001 
C-Jun & c-Fos 0.182 
SOX9 0.933 
CDX2 & HNF4-α 0.000 
HNF4-α 0.406 
PGL4.10 [luc2] 0.134 
GFP 0.269 
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The Luc/β-gal ratios for each sample were then compared against the Luc/β-gal ratio of the control, 
pGL 4.10 [luc2, SOX9]. All samples showed significant differences, except for the samples treated 
with CDX2 and TCF4. The CDX2 + HNF4-α, SP1, and p65 + p52-treated samples were not 
analyzed due to lack of reproducibility across the 1:3 and 1:4 clones. 
 
Table 3: Statistical analysis of data using Student T-Test 
 
1:3 samples p Mean Std Dev 
PGL 4.10 [luc2, SOX9] 1.000 0.046 0.001 
TCF4 0.067 0.064 0.013 
CDX2 0.144 0.053 0.007 
p65 + p50 0.000 0.029 0.002 
p65  + p52 0.002 0.326 0.051 
SP1 0.043 0.057 0.007 
C-Jun & c-Fos 0.007 0.029 0.006 
SOX9 0.016 0.035 0.005 
CDX2 & HNF4-α 0.000 0.004 0.001 
HNF4-α 0.003 0.216 0.037 
PGL4.10 [luc2] 0.000 0.001 0.000 
GFP  0.037 0.039 
 
1:4 samples p Mean Std Dev 
PGL 4.10 [luc2, SOX9] 1.000 0.057 0.010 
TCF4 0.371 0.068 0.018 
CDX2 0.276 0.050 0.005 
p65 + p50 0.043 0.040 0.008 
p65  + p52 0.000 0.235 0.016 
SP1 0.007 0.029 0.004 
C-Jun & c-Fos 0.007 0.024 0.001 
SOX9 0.020 0.035 0.003 
CDX2 & HNF4-α 0.000 0.234 0.011 
HNF4-α 0.000 0.235 0.017 
PGL4.10 [luc2] 0.002 0.000 0.000 
GFP  0.010 0.012 
 
All	  samples	  were	  compared	  to	  the	  control,	  pGL	  4.10	  [luc2,	  SOX9],	  using	  2-­‐tailed	  independent	  sample	  t-­‐test.	  
In	  both	  the	  1:3	  and	  1:4	  clones,	  all	  samples	  except	  those	  treated	  with	  TCF4	  and	  CDX2	  showed	  a	  significant	  
difference	  in	  SOX9	  promoter	  activity	  (α	  =	  0.05). 
Performing a two-tailed Student’s t-test with α = 0.05 to compare each sample to the 
control, pGL 4.10(2.8 ng/µl), gives the following results: p65 + p50 (p = 0.043), p65 + p52 (p < 
0.001), SP1 (p = 0.007), cJun + cFos (p = 0.007), SOX9 (p = 0.020), CDX2 + HNF4-α (p < 0.001), 
and HNF4-α (p < 0.001) all deviate significantly from controls. Samples treated with TCF4 (p = 
0.371) and CDX2 (p = 0.276) do not deviate significantly from controls.	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Discussion	  	  
SOX9 is needed in the intestinal and colon epithelium to maintain homeostasis by inducing 
differentiation in the proliferative cells [Blache et al., 2004]. The lack of SOX9 results in abnormal 
proliferation and morphology, however no carcinoma was detected in mice lacking the Sox9 gene 
expression in the intestinal and colon epithelium [Bastide et al., 2007]. This means that absence or 
underexpression of SOX9 is not lethal or does not induce cancerous cells [Bastide et al., 2007]. 
Conversely, SOX9 is expressed when Wnt signaling is active and because Wnt pathway is up 
regulated in cancer cells, SOX9 gene is strongly expressed as well [Reya and Clevers, 2005]. In 
turn, SOX9 can decrease β-catenin-TCF4 activity when it is overexpressed and thus regulate the 
Wnt pathway [Blache et al., 2004].  Given SOX9 functions in intestinal and colon epithelium and 
its connection to Wnt and other transcriptional pathway, in this study, we investigated several 
transcription factors that might influence SOX9 expression and therefore the development of 
colorectal cancer. This was done by implementing the SOX9 promoter in front of a luciferase 
reporter gene in the vector pGL4.10 and co-transfected it with the chosen transcription factors. 
In colon carcinoma, high expression of SOX9 has been identified in the same cells where the 
β-catenin-TCF4 complex was active, which suggests a correlation [Blache et al., 2004]. TCF4 is a 
transcription factor that suppresses expression of genes from the Wnt pathway, but acts as an 
activator when it is bound by β-catenin [Korinek et al., 1998]. Furthermore, when β-catenin-TCF4 
complex was not able to associate due to a TCF4 mutant that lacks β-catenin binding site, SOX9 
was not expressed. This might further imply that SOX9 expression is driven by β-catenin-TCF4 
association, which suggests that SOX9 is a downstream target of Wnt signaling [Blache et al., 
2004]. Tcf4 knockout mice fail to express Sox9 in the intestinal epithelium [Blache et al., 2004]. 
From our results, SOX9 promoter activity is not significantly affected when co-transfected with 
TCF4. This means that endogenous TCF4 levels are required to express SOX9, however, higher 
levels of TCF4 do not result in a change of SOX9 expression.  
In addition, we found that CDX2 has no statistically significant influence on SOX9 promoter 
activity. It has been shown that SOX9 represses CDX2, which is a tumor suppressor gene that 
regulates cell growth and differentiation in intestinal epithelium [Suh and Traber, 1996]. CDX2 is 
mainly found in the villi in the small intestine and is expressed in colon cancer at very low levels 
[Uesaka et al., 2004]. Many studies have highlighted the tumor suppressor function of CDX2 due to 
its ability to reduce proliferation in some molecular profiles of colon cancer, and due to its absence 
from the tumor cells [Suh and Traber, 1996; Ee et al., 1995]. Furthermore, Cdx2 knockout mice 
displayed more tumors than wild-type mice when exposed to the carcinogen azoxymethane or when 
crossed with tumorigenic mice [Aoki et al., 2003].  In contrast, CDX2 has also been correlated with 
a tumor inducing function in at least two studies. They have suggested that CDX2 expression 
enhances cell survival by activating expression of the anti-apoptotic Bcl-2 protein [Witek et al., 
2005; Dang et al., 2006]. Our investigation of the influence of CDX2 on the SOX9 promoter 
activity, we have found that the level of the reporter protein luciferase does not change when co-
transfected with CDX2 compared to the control. CDX2 tumor suppressor mechanism depends on its 
binding to β-catenin and impeding β-catenin-TCF4 association hence inhibiting the Wnt pathway 
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[Guo et al., 2010]. However, SOX9 expression is dependent on the β-catenin-TCF4 complex and 
since this complex does not get formed that often, lower SOX9 promoter activity should be the 
outcome. This might be because CDX2 is mainly found in the villi and poorly expressed in the 
crypts while SOX9 is mostly expressed in the crypts. 
Sp1, c-jun together with c-fos, and p65 with p50 transcription factors exhibit a statistically 
significant suppression of SOX9 promoter activity. 
The protein c-Jun is the main factor in the JNK pathway and it has been shown to directly 
regulate Wnt signalling which controls proliferation and SOX9 expression. c-Jun plays an essential 
role in differentiation and apoptosis. Together with c-Fos, c-Jun forms a complex that results in the 
formation of Activator Protein-1 (AP-1) [Chiu et al., 1988]. The AP-1 complex binds to promoter 
regions of DNA at AP-1 specific sites and enhances target genes [Chiu et al., 1988].  It is 
phosphorylated and activated by the JNK pathway [Fang and Richardson, 2005]. Increased activity 
of the JNK pathway has been found in human tumors. The overexpression of c-jun results in 
increased proliferation and migration of cells towards the top of the crypts and villi making them 
longer while the absence of c-Jun decreases proliferation and villi length. In addition, c-Jun directly 
binds the TCF4 gene. TCF4 protein is highly expressed in tumour cells that express c-Jun. Binding 
of c-Jun protein to the TCF4 promoter increases the expression of TCF4 resulting in the Wnt 
pathway being strongly activated [Sancho et al., 2009]. Since the Wnt pathway is up-regulated in 
the presence of c-jun, SOX9 would be more expressed as well, however, our experiment shows that 
SOX9 promoter activity is decreased when it is co-transfected with c-Jun and c-Fos. This might be 
due to AP-1 complex not having a high affinity for the TCF4 promoter compared to c-Jun alone 
[Sancho et al., 2009], therefore, the Wnt pathway is not as active. Alternatively, c-Jun and c-Fos 
dimer may directly binds the SOX9 promoter and suppresses it. It is also uncertain if c-Jun and c-
Fos formed the AP-1 dimer and therefore may be competing in the binding to binding sites.  
In addition, from our data showing that SOX9 reduces the SOX9 promoter activity it can be 
suggested that SOX9 has a negative feedback mechanism on itself. There has not been much (or 
any) research done on the effects of SOX9 upon itself, therefore we cannot compare any other 
findings. Additional research is needed in order to confirm this negative feedback. However, from 
our research the data was replicable between the two clones.    
Hepatocyte nuclear factor 4 alpha (HNF4-a) is a part of the nuclear receptor superfamily of 
ligand-dependent transcription factors. HNF4-a acts as a tumor suppressor in hepatocytes but its 
function in the small intestine and colon is not well understood [Bolotin et al., 2010]. The absence 
of HNF4-a in colon resulted in inability to develop crypts [Garrison et al., 2006]. It is not yet 
decided if HNF4-a acts as an oncogene or a tumor suppressor [Schwartz et al., 2009]. The reason 
might be because of the different isoforms of the HNF4-a protein. Two promoters express HNF4-a: 
P1 and P2. Their proteins differ in 16 - 29 amino acids [Bolotin et al., 2010]. It has been shown that 
P1-HNF4-a is missing in 80% of colorectal cancers while P2-HNF4-a is unaffected [Chellappa et 
al., 2012]. 
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Our results show that SOX9 promoter is highly enhanced when co-transfected with HNF4-a. 
As much as four times higher luciferase expression was detected compared to SOX9 promoter 
activity transfected alone. The mechanism by which HNF4-a helps maintain intestinal epithelium 
homeostasis involves the Wnt pathway. When HNF4-a is not expressed, increased proliferation in 
the intestinal crypts is observed which suggests that the Wnt pathway is more active than normal 
[Cattin et al., 2009]. The expression of TCF4 is up-regulated in the absence of HNF4-a, however, 
when HNF4-a gets expressed, the β-catenin-TCF4 transcriptional activity is reduced. Furthermore, 
it has been shown (through immuno-precipitation) that HNF4-a binds TCF4 and impedes it to 
associate with β-catenin, which results in repression of Wnt genes transcription [Cattin et al., 2009]. 
Given the fact that SOX9 expression depends on Wnt signaling, more specifically on β-catenin-
TCF4 association as mentioned above, co-transfection of SOX9 promoter with HNF4-a plasmid 
should result in lower SOX9 promoter activity instead of four-fold increase. This might suggest that 
HNF4-a directly binds the SOX9 promoter enhancing it despite the fact that it also acts to inhibit the 
Wnt pathway, which would affect SOX9 expression negatively. 
Co-transfection of the SOX9 promoter with CDX2 and HNF4-a plasmids gives opposite 
results in the two clones, however, the case in which SOX9 promoter is enhanced gives more 
meaning since: first, CDX2 alone does not have any effect on the SOX9 promoter, secondly HNF4-
a enhances the activity greatly, and thirdly it has been further shown that HNF4-a binds to the 
CDX2 promoter and inhibits its transcription [Boyd et al., 2009]. It is also apparent from our data 
that the results from which CDX2 and HNF4-a reduce SOX9 promoter activity can be disregarded 
due to their activity levels being lower than the levels found in the vector alone without the SOX9 
promoter insert.  
Another transcription factor which gave inconsistent and unreplicable results is the 
specificity protein 1 (Sp1). Sp1 plays a role in the development and progression of several types of 
cancers and it has been found to be expressed in 74% of colon cancer tissue [Zhao et al., 2013]. Sp1 
is involved in gene expression in early development of organism where it helps in regulating cell 
proliferation, differentiation, apoptosis, drug resistance, and metastasis [Tian et al., 2011; Jungert et 
al., 2007]. It has been found that Sp1 is overexpressed in colon cancer tissue [Zhao et al., 2013]. To 
our knowledge no studies have investigated the influence of Sp1 on the SOX9 promoter in intestinal 
or colon epithelium. However, it has been shown that Sp1 binds the SOX9 promoter at two sites in 
chondrocytes. Furthermore, mutation in one of the sites (Sp1-1) resulted in a lower activity of the 
SOX9 promoter, hence Sp1 binding enhances its activity [Velazquez et al., 2007]. In our study, the 
1:3 clone indicates that Sp1 increases SOX9 promoter activity while the 1:4 clone shows a decrease 
in promoter activity. This could perhaps be explained due to the two Sp1 binding sites found in the 
SOX9 promoter, the Sp1-1 and Sp1-2, depending on which our Sp1 binds to it could result in 
different SOX9 promoter activity.  We did not have a mutation or deletion in the Sp1-1 binding site 
as demonstrated by Velazquez could resulted in Sp1 enhancing activity as seen in the 1:3 clone 
[2007]. This can be seen in figure 6 of our sequencing data.   
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Figure 6: Sequencing data of our 1:3 and 1:4 clones. The Sp1-1 binding site is located 
at 298 to 310 (sequence CCCCCCGCCCCCC). The Sp1-2 binding site is located from 339-347 
(sequence CCCCTCCCC) 
The nuclear factor-κβ, NF-κβ, has been found to be active in all cells. It has been shown that 
NF- κβ regulates a variety of genes involved in cell proliferation, tumorigenesis and metastasis in 
cancer and it is therefore an area of interest if it is involved in regulating SOX9 [Wang et al., 2009]. 
P65/P50 and P65/P52 are both transcriptional regulators dimers of the NF- κβ. It is apparent that 
NF- κβ has a function that is necessary for linking inflammation with cancer, such as the increased 
risk of patients with chronic inflammation in the bowels developing colorectal cancer [Want et al., 
2009; Lei Sun et al., 2013].  
The inflammatory site releases cytokines and chemokines, which enhance the survival of 
premalignant cells by activating NF-κβ. NF-κβ can block apoptosis by regulating anti-apoptosis 
proteins, or by inhibiting apoptosis by inhibiting prolonged c-Jun N-terminal kinases (JNK) 
activation [Want et al., 2009].  It is suggested that NF-κβ activation generally occurs prior to 
metastatic spread of colorectal cancer [Puvvada et al., 2010].  A study by Lei Sun et al. found 
extremely high levels of luciferase activity when the SOX9 promoter was transfected into PANC1 
cells (pancreatic cancer stem cells) together with p65 + p50 [2013]. This activity was drastically 
reduced when treated with a NF-κβ inhibitor. This suggest that NF-κβ signalling positively 
regulates SOX9 expression by binding directly to the promoter in pancreatic cancer cells [Lei Sun et 
al., 2013]. From our results it can be suggested that p65 + p52 may act in a similar way as in 
pancreatic cancer by greatly increasing the SOX9 promoter activity. In contrast, our results suggest 
that p65 + p50 acts opposite of how it is found in pancreatic cancer, greatly decreasing the SOX9 
promoter activity. Additional research needs to be conducted in different cell lines of colorectal 
cancer to confirm.  
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Part	  III:	  Supplementary	  Material	  
1.	  Colorectal Cancer Molecular Profiles	  
The process of colorectal carcinogenesis is the adenoma-carcinoma sequence (a general 
description of the genetic abnormalities in the progression of colorectal cancer) and the multistep 
formation of tumours; this is determined by gatekeeper and caretaker molecular pathways 
[Cunningham et al., 2010].  Classification systems have been developed of the molecular profiles 
colorectal cancer, two of these classes being genetic instability. Eighty five percent of sporadic 
cases have chromosomal instability (allelic imbalance at several chromosomal loci), and 
chromosome amplification and translocation. This contributes to tumour aneuploidy, having an 
abnormal number of chromosomes in a cell [Cunningham et al., 2010].  Fifteen percent of cases 
have the high-frequency microsatellite instability phenotypes, including cases such as frameshift 
mutations and base-pair substitutions that commonly arise in short tandemly repeated nucleotide 
sequences (microsatellites) [Cunningham et al., 2010].  Microsatellite instability arises from the 
inability of the DNA nucleotide mismatch repair system to correct errors often occurring during 
DNA replication. A epigenetic silencing of the DNA mismatch-repair genes (such as MLH1, MSH2, 
and MSH6) contributes to this phenotype [Cunningham et al., 2010].  
Most cases of colorectal cancer occur sporadically. The highest risk factor being age and 
accumulate mutations. Other risk factors include male sex, previous colonic polyps or cancer, and 
environmental factors usually associated with highly developed countries (eg. red meat, high-fat 
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diet, inadequate intake of fiber, obesity sedentary lifestyle, diabetes mellitus, smoking, and high 
consumption of alcohol) [Labianca et al., 2010].  Inflammatory bowel diseases (ulcerative colitis 
and Crohn's disease) are often also associated with colorectal cancer, with about 65% of colorectal 
cancer cases being associated [Cunningham et al., 2010*; Jawad et al., 2011].  Hereditary colorectal 
cancer is much less common than sporadic colorectal cancer. Approximately one in 300 cases of 
colorectal cases are caused by Lynch syndrome, also known as hereditary non-polyposis colorectal 
cancer. Familial adenomatous polyposis is much less frequent, only being found in about one in 
7000 patients with colorectal cancer, while MYH-associated polyposis occurs in about one in 
18,000 individuals with colorectal cancer.    
The epithelium of the small intestine and colon is the fastest self-renewing tissue in 
mammals. The surface of the small intestine has two defined regions: the crypts of Lieberkuhn 
which are invaginations in the in the epithelium and finger-like villi. The crypts contain the adult 
stem cells and Paneth cells which are considered the proliferative part of the intestinal epithelium. 
Paneth cells and villi are not found in the colon. In the small intestine, Paneth cells migrate to the 
bottom of the crypt and remain adjacent to the stem cells in order to protect from bacteria by 
secreting antimicrobial compounds [Stappenbeck et al., 1998]. The villi shelter the differentiated 
cells, which move upwards from the stem cells. There are three different types of differentiated 
cells in the villi: the goblet cells which secrete mucus in order to protect and lubricate the 
epithelium surface, the enterocytes which are the intestinal absorptive cells that uptake water and 
nutrients and lastly, enteroendocrine cells which produce hormones in response to stimuli and 
release them into the bloodstream [Reya and Clevers, 2005]. 
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Figure	  1:	  Structure	  of	  the	  small	  intestine	  and	  the	  colon	  [Goodell	  et	  al.,	  2015]	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2.	  Signalling	  Pathways	  and	  Transcription	  Factors	  Studied	  
2.1	  Wnt	  signalling	  
SOX9 - Wnt interaction in intestinal epithelium helps hold homeostasis during constant cell 
renewal [Kormish et al., 2009]. However, increased activation of Wnt pathway has been associated 
with cancer development [Wend et al., 2010]. Wnt signalling coordinates stem cells proliferation in 
the crypts but SOX9 is needed in order to disrupt the cell cycle and further differentiate them. An 
analysis of this pathway is conducted in order to identify what Wnt components influence SOX9 
expression in intestinal epithelium and in colon. 
 
2.1.1	  The	  Wnt	  pathway	  in	  Embryogenesis	  and	  stem	  cells	  
The processes controlled by Wnt signalling in embryogenesis are body axis patterning, cell 
proliferation and migration and cell differentiation. The Wnt proteins are highly conserved in 
mammals, which means that they are similar across species (from drosophila to humans). 
Wnt signalling cascade plays an important role in stem cell differentiation during 
embryogenesis and in adult stem cells which helps insure homeostasis in self-renewal processes and 
act in tissue repair during injury. Wnt signalling also induces cell differentiation. This was 
demonstrated upon inhibition of the pathway which resulted in no differentiation of Paneth, goblet 
and enteroendocrine cell kinds [Pinto et al., 2003]. Lastly, Wnt signalling plays a role in the 
migration of the different cell types in the epithelium by regulating the expression of Eph/Ephrin 
surface molecules which are in charge of the proper position of the cells along the villi - crypts 
space [Batlle et al., 2002]. 
The first step in the canonical Wnt pathway is the attachment of the Wnt protein to G 
protein coupled receptors (from the Frizzled family) with the help of co-receptors (lipoprotein 
receptor-related protein LRP 5/6) which leads to accumulation of β-catenin in the cytosol. Next, β-
catenin is further translocated into the nucleus where it binds cf/Lef transcription factors family in 
order to activate Wnt genes [Branties et al., 2002] (See Figure 2b).  
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Figure	  2:	  The	  canonical	  Wnt/β-­‐catenin	  pathway.	  Binding	  of	  Wnt	  to	  the	  receptors	  Fizzled	  (Fz)	  and	  LRP6	  leads	  to	  inhibition	  of	  β-­‐
catenin	  degradation.	  β-­‐catenin	  pathway	  in	  turn	  interacts	  with	  members	  of	  the	  TCF/Lef-­‐1	  family	  of	  transcription	  factors	  to	  co-­‐
active	  target	  gene	  transcription	  (Sawa	  and	  Korswagen).	   
Without Wnt signalling (see figure 2a), β-catenin gets destroyed by a complex that includes 
the two tumour suppressors Axin and adenomatous polyposis (APC) which bind β-catenin. In 
addition to these, the complex contains two kinases: glycogen synthase kinase 3 (GSK3) and casein 
kinase 1a (CK1a) which phosphorylate Serine and Threonine residues in the N terminus of β-
catenin. Following phosphorylation, β-catenin gets degraded. The degradation complex is 
inactivated by translocation to the plasma membrane when Wnt binds the Frizzled receptors. This 
process is not entirely understood, but it is assumed that Axin binds the co-receptor LRP 5/6 and its 
levels decrease as result of dephosphorylation [Behrens et al., 1996]. 
 
2.1.2	  The	  Wnt	  pathway	  in	  colon	  cancer	  
The most studied gene in regards to cancer from the pathway is the APC gene which has as a 
product the APC protein from the degradation complex of β-catenin. An APC defective allele leads 
to development of adenomas in the colon and it is the basis of a hereditary syndrome called familial 
adenomatous polyposis (FAP) [Kinzler and Vogelstein, 1996]. An improper APC protein is not able 
to degrade β-catenin, which keeps building up in both the cytosol and nucleus and associates with 
TCF4 and results in elevated transcription of Wnt genes. This increased complex association leads 
to SOX9 overexpression, which means that APC affects SOX9, levels indirectly [Blache et al., 
2004]. On the other hand, when APC is overexpressed, it leads to cell cycle arrest between G1 and 
S phase. Overexpression in colon cancer cells results in apoptosis, which is consistent with APC 
role as tumour suppressor. Besides a faulty APC inherited allele, there are also somatic mutations 
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that can occur in the APC gene. The effect of these mutations will be increased β-catenin levels and 
an increase of β-catenin/Tcf complex formation [Polakis, 1997].  
β-catenin might also malfunction and can lead to colorectal cancer even when APC works 
well. Mutations in phosphorylation site will impede phosphorylation and β-catenin will not be 
broken down. The resulting β-catenin elevated levels will pair up with Tcf/Lef transcription factors 
and activate Wnt target genes more than normal one of those genes being SOX9. Mice with 
overexpression of β-catenin have been found to have abnormal growth in the small intestine with 
three to four times increase in the levels of apoptotic cells from the villi [Harada et al., 1999]. In 
contrast, another study on these kind of transgenic mice has shown that the villi are more branched 
and an increased proliferation of stem cells but no oncogenic effect [Wong et al., 1998]. SOX9 
represses the target genes of β-catenin that promote proliferation (c-myc and cyclic-D1) and also 
increases transcription of β-catenin-TCF inhibitors. Both processes are supposed to keep in balance 
proliferation-differentiation ratio in the intestinal epithelium [Bastide et al., 2007]. 
Axin is a protein that interacts with β-catenin, GSK3 and APC and its overexpression lowers 
β-catenin levels in colorectal cancer cells. Axin acts as a bridge between β-catenin and GSK3 and 
deletion of either β-catenin or GSK3 binding region fails to degrade β-catenin, which supports the 
idea, that Axin facilitates the phosphorylation of β-catenin by GSK3 [Sakanaka et al., 1998]. Axin 
is regulated by Wnt signalling which induces its dephosphorylation making it more unstable and 
less efficient in binding β-catenin. Therefore, binding of Wnt protein to Frizzle receptors impedes 
axin to facilitate connection between β-catenin and GSK3 which results in a failed phosphorylation 
and build up of β-catenin that in turn activates transcription together with Tcf/Lef [Ikeda et al., 
1998].   
Overall, different malfunctions in Wnt pathway have as a consequence either higher or 
lower β-catenin-TCF4 activation which directly regulates the levels of SOX9 expression [Blache et 
al., 2004].  
	  
2.2	  Mitogen-­‐activated	  Protein	  Kinase	  (MAPK)	  
The mitogen-activated protein kinases (MAPK) signalling pathway is related to colon 
cancer by its ability to regulate transcription factors. The pathway is a chain of proteins in the cell 
that are involved in the communication of signals from a receptor on the surface of the cell to the 
DNA of the nucleus. It is one of the most studied signalling pathways because it governs the 
growth, proliferation, differentiation, survival and apoptosis of many cell types [Orton et al., 2005; 
Slattery et al., 2013]. There are three major subfamilies of the MAPK signalling pathway: the 
extracellular signal regulated kinases (ERK MAPK or Ras/Raf1/MEK/ERK); the c-jun N-Terminal 
kinase or stress-activated protein kinases (JNK or SAPK); and MAPK14 [Fang and Richardson, 
2005]. The ERK MAPK pathway (seen in figure 2) is essential for cell proliferation. It is located 
downstream of many growth factors, such as the Epidermal Growth Factor (EGF), such as for the 
intestinal cell differentiation. The overexpression and activation of this receptor is often found in 
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colorectal cancer, and it has been suggested that the overexpression of this pathway is an important 
part in the development of colorectal cancer [Fang and Richardson, 2005]. Phosphorylate 
neighbouring proteins, increasing the phosphorylated proteins activity [Orton et al., 2005]. 
 
 
2.3	  ERK	  MAPK	  pathway	  signalling	  
The MAPK pathway consists of 3-tiered cascade cycles that include kinases and phosphatases cycles 
(Figure 2) [Slattery et al., 20013; Orton et al., 2005].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	  3:	  The	  three	  major	  subfamilies	  of	  the	  MARK	  Signal	  Pathway:	  ERK	  MAPK,	  JNK,	  and	  MAPK14	  [Fang	  and	  Richardson,	  2005]	   
The pathway starts by a signal being transmitted through protein kinase C (PKC) or Ras 
trigger ERK pathway signalling, initiating the creation of a receptor signalling complex [Orton et 
al., 2005; Fang and Richardson, 2005]. This initiates an activation cascade involving MEK and 
ERK. The activation of PKC promotes the binding of a GTP to Ras (active form), replacing a GDP 
(inactive form). GTP-Ras then interacts with Raf1, leading to its activation which then leads to 
MAPK activation. The activated Raf1 serine-phosphorylated MEK1 and MEK2 (ERK kinases), 
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which then phosphorylates ERK. The ERK kinases, MEK 1/2, have dual function in the MAPK 
cascade. They control cell growth and differentiation. Their activation occurs by a wide range of 
growth factors and cytokines and also by membrane depolarisation and calcium influx. There are 
multiple subtypes of ERK: ERK 1, 2, 3, 4, 5, and 6. The ERK enzyme can phosphorylate 
cytoplasmic targets or move into the nucleus where it can phosphorylate and activate several 
transcription factors.  ERK 1 and 2 activation causes phosphorylation of transcription factors, and 
therefore activating them regulates genes which increase cell proliferation and protect the cell 
against apoptosis. 
Activation of this pathway has shown to induce the production of cyclin D1, which promotes 
cell division [Fang and Richardson, 2005].  Ras/Raf/MEK/ERK signals can either initiate cellular 
proliferation or differentiation, depending on the duration and intensity of the signal. A short signal 
of ERK activation favors the promotion of proliferation, while a long signal promotes 
differentiation [Fang and Richardson, 2005]. 
	  
2.4	  JNK	  and	  MAPK14	  pathway	  signalling	  
The kinases of the JNK pathway are encoded by three genes: MAPK8, MAPK9, and 
MAPK10 [Fang and Richardson, 2005]. These proteins they encode are spliced to form the JNK 
isoforms. Together with the ERK 1 and 2 the JNK are essential for the phosphorylation of 
activating protein 1 (AP1).  This phosphorylation is activated by stress and exposure to various 
cytokines. Protein kinase G (PKG)/MEKK1/SEK1/JNK cascade activates the JNK proteins. This 
pathway plays a significant role in cell proliferation and inducing apoptosis. 
MAPK14 has also been shown to play a crucial role in cell proliferation and differentiation, 
however instead of inducing apoptosis, it has been shown to protect cells from it [Fang and 
Richardson, 2005]. 
 	  
2.5	  MAPK	  in	  Colorectal	  Cancer	  
The ERK MAPK cascade has been found to be down-regulated in about 30% of all cancers 
[Fang and Richardson, 2005]. This cascade is involved in the control of growth signalling, cell 
survival, and invasion of cancer. In the case of colorectal cancer the cells escape from the normal 
growth pattern and differentiation control and then develop the ability invade surrounding tissue 
and organs.   
Ras has been found to be mutated in about 36% of colorectal cancer, the mutation of gene 
KRAS proto-oncogene has been recognized in the early development of these cancers. Increased Ras 
activity, due to the mutations, results in increased ERK activity. In cell lines from human colorectal 
cancer, activated Ki-Ras-mediated signals have been found to be involved in the activation of the 
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SEK1-JNK pathway through a PKC isotype [Fang and Richardson, 2005]. This isotype is distinct 
from that which is involved in MEK-ERK activation and is independent of activation of PI3 kinase 
[Fang and Richardson, 2005].  This imbalance, created by the Ki-Ras of the ERK and JNK activity 
could play a crucial role in the development of human colorectal tumorigenesis. 
A mutation of the gene BRAF, a serine-threonine kinase of the Raf family, results in increased 
kinase activity [Fang and Richardson, 2005]. This mutation has been found in 9-11% of colorectal 
cancers [Fang and Richardson, 2005]. Mutations of BRAF have frequently been found in sporadic 
colorectal cancer with microsatellite instability. 
The transcription factor c-Jun plays an essential role in differentiation and apoptosis. It is 
phosphorylated and activated by the JNK pathway (as seen in figure 3) [Fang and Richardson, 
2005]. Increased activity of the JNK pathway has been found in human tumours [Fang and 
Richardson, 2005]. 
There are many mechanisms that lead to the increase ERK-MAPK signalling that can 
contribute to the development of colorectal cancer.  Another such mechanisms is the up-regulation 
of the Epidermal Growth Factor (EGF) receptor, which activates the ERK/MAPK signalling, 
therefore resulting in increased mitogenesis [Fang and Richardson, 2005]. 
It has been suggested by several studies that the ERK MAPK pathway is the major regulator 
of cell proliferation in colorectal cancer, compared to the JNK and p38 MAPK pathway [Fang and 
Richardson, 2005]. 	  
3.	  Transcription	  factors	  
3.1	  SOX9	  	  
SOX9 is a part of a HMG-box (high motility group) transcription factors and it is necessary 
for committed cell differentiation, as in chondrogenesis, male sex gonad or respiratory epithelium 
development, melanocyte differentiation, and the differentiation of Paneth cells in the gut. SOX9 
plays a role in differentiation of stem cells in the intestinal epithelium. It is mainly expressed in the 
intestinal stem and Paneth cells but its roles in these cells are not very well determined yet [Blache 
et al., 2004]. 
When Sox9 gene is not expressed in mice, differentiation of Goblet cells is decreased and 
Paneth cells are completely absent. An increased number of stem cells was also observed in the 
crypts which might suggest that Sox9 is involved in regulation of stem cell population. The intestine 
crypts had an altered shape and abnormal cell proliferation was detected. In addition, colon 
morphology was severely affected by folding and developed villi like areas [Bastide et al., 2007]. 
These changes in the structure of the small intestine and colon suggests that Sox9 is important in 
their morphology maintenance and that Sox9 down-regulates the Wnt pathway by stopping 
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proliferation and make the stem cell differentiate instead. No carcinoma was detected in these mice 
lacking Sox9 even after half a year which means that SOX9 deficiency alone is not able to induce 
cancerous cells [Bastide et al., 2007].  
On the other hand, SOX9 is expressed when Wnt signalling is active and because Wnt 
pathway is up regulated in cancer cells, SOX9 gene is strongly expressed as well. In colon 
carcinoma cells, high expression of SOX9 has been identified in the same cells where β-catenin-
TCF4 complex was active, which suggests a correlation between them. Furthermore, when β-
catenin-TCF4 complex was not able to associate due to a TCF4 mutant that lacks β-catenin binding 
site, SOX9 did not get expressed. This might further imply that SOX9 expression is driven by β-
catenin-TCF4 association [Blache et al., 2004]. Furthermore, TCF4 knockout mice fail to express 
SOX9 in the intestinal epithelium. SOX9 can decrease β-catenin-TCF4 activity when it is 
overexpressed and by this, helps keep in control the Wnt pathway [Bastide et al., 2007]. 
In order to find out if SOX9 repression is directly triggered by interference in the Wnt 
signalling and not as a consequence of the changes in cell physiology induced by the pathway, 
levels of SOX9 were measured after inhibition of β-catenin-TCF4 with GFP-cyt-E-cadherin. After 8 
hours, the cells transfected with cyt-E-cadherin had significant lower SOX9 proteins expressed, 
while after 16 hours no SOX9 was present. Conversely, the cells transfected only with GFP had the 
same amount of SOX9 expressed even after 48 hours. This shows that Wnt signalling is a major 
regulator of SOX9 [Blache et al., 2004]. 
It has been shown that SOX9, even though it is expressed mainly in the undifferentiated cells 
from the crypts, regulates genes from more differentiated cells that are located in the villi. More 
specifically, SOX9 represses CDX2 transcription, which encodes for transcription factors that 
induce cell differentiation in villi [Silberg et al., 2000].  
In conclusion, increased Wnt signalling leads to overexpression of SOX9 while, inactivation 
of this pathway represses SOX9. In turn, by a negative loop, SOX9 represses Wnt signalling keeping 
proliferation under control [Bastide et al., 2007]. A strict balance is needed between proliferation, 
migration, differentiation and cell death, and when this fails, intestinal cancer can be developed as a 
consequence of elevated Wnt signalling [Bastide et al., 2007]. 
 
3.2	  CDX2	  
CDX2 is an intestinal transcription factor that is mainly found in the villi where it induces 
growth retardation and cell differentiation. It is involved in anterior-posterior patterning of the 
intestinal epithelium and in the process of cells differentiation. When CDX2 is expressed in the 
crypts, it induces differentiated cells with enterocyte and goblet properties [Suh and Traber, 1996]. 
It has been designated as an important biomarker in colorectal adenomas and well-differentiated 
cancers and it is poorly expressed in undifferentiated and moderately differentiated cancers 
[Kaimaktchiev et al., 2004].  
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Guo and colleagues [2004] have shown that colon cancer cell proliferation was decreased 
when CDX2 was expressed because it disrupted the β-catenin-TCF4 complex from the Wnt 
pathway, which means that CDX2 acts as a tumour repressor. They also determined that colon 
cancer cells significantly reduce the CDX2 inhibition activity on the β-catenin-TCF4 complex. 
They further investigated the mechanism by which CDX2 affects the complex. They pointed out 
that the CDX2 protein binds β-catenin, which prevents its association with TCF4 transcription 
factor [Guo et al, 2010].  
Many other studies have highlighted the tumour suppressor function of CDX2 because it can 
reduce proliferation in some colon cancer and also because of its absence from the tumour cells 
[Suh and Traber, 1996; Ee et al., 1995]. Furthermore, mice with a deleted Cdx2 allele displayed 
more tumours than normal mice when exposed to the carcinogen azoxymethane or when crossed 
with tumorigenic mice [Aoki et al., 2003]. In contrast, CDX2 has also been correlated with a tumour 
inducing function in at least two studies. They have suggested that CDX2 expression enhances cell 
survival by activating expression of the anti-apoptotic Bcl-2 protein [Witek et al., 2005; Dang et al., 
2006]. Based on these two opposing functions, a mechanism of CDX2 was hypothesized. The 
tumour suppressor activity counts on the protein-protein interaction between CDX2 and β-catenin 
that impedes β-catenin-TCF4 association [Guo et al, 2010]. Processes that increase β-catenin or 
reduce CDX2 levels result in higher Wnt signalling and uncontrolled proliferation. In colon cancer, 
this decrease in CDX2 proteins is due to ubiquination and proteosome degradation [Boulanger et 
al., 2005]. Even though the CDX2 proteins get degraded, CDX2 transcriptional activity remains 
intact and may promote tumorigenesis due to anti-apoptotic factors expression [Dang et al., 2006].   
 
3.3	  TCF4	  
TCF4 is a part of TCF transcription factors downstream the Wnt pathway. They are cell 
type-specific and contain a DNA-binding high mobility group (HMG) box and a β-catenin binding 
domain. Their transcriptional activity is induced by the binding of either co-repressors or co-
activators. TCF4 suppresses transcription of genes from the Wnt pathway, but acts as an activator 
when β-catenin is present [Korinek et al., 1998]. TCF4 is expressed in the entire crypt-villus axis in 
the small intestine. In regards to the colon, there are lower TCF4 levels in the proliferative cells 
from the crypts with increasing levels towards the more differentiated cells closer to the epithelium 
surface. This means that the levels of TCF4 along the crypts act like a switch from proliferation to 
differentiation [Van Es et al., 2012].  
The gene encoding Tcf4 in mice is Tcf7/2 and when one allele was deleted in embryonic 
mice, they die shortly after birth. They lacked proliferative cells in the crypts and instead fully 
differentiated cells were observed [Korinek et al., 1998]. This implies that Tcf4 is vital in stem cells 
renewal and that higher association of β-catenin-Tcf4 complex in the small intestine and colon 
results in tumorigenesis [Tang et al., 2008].  
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In addition, individual inactivation of the main effectors in the Wnt signalling (Tcf1, Tcf2 
and Tcf4) demonstrated that Tcf4 is the most important transcription factor in the regulation of 
intestinal epithelium while the other two effectors do not display significant functions [Van Es et 
al., 2012].  
In contrast, an in vivo study by Angus-Hill et al., [2011] has shown that one allele 
inactivation of Tcf4 in colon results in increased proliferation and therefore it acts as a tumour 
repressor. They concluded that Tcf4 modulates cell proliferation in colonic epithelium and that its 
absence leads to tumor formation [Angus-Hill et al., 2011]. 
	  
3.4	  HNF4α	  
Hepatocyte nuclear factor 4 alpha (HNF4α) is a part of the nuclear receptor superfamily of 
ligand dependent transcription factors. It is mainly found in the liver, pancreas, kidney, small 
intestine and colon and plays a role in epithelial cells development. It has been widely studied in 
liver and when mutated it has been associated with the onset of Type II diabetes. HNF4α acts as a 
tumor suppressor in hepatocytes but its function in the small intestine and colon is not well 
understood [Bolotin et al., 2010]. In intestinal epithelium HNF4a is found along the crypt-villus 
axis except in the very bottom of the crypts [Stegmann et al., 2006]. The absence of HNF4a in 
colon resulted in inability to develop crypts [Garisson et al., 2006]. Hnf4a knock-out adult mice in 
the intestinal epithelium and colon respectively showed that this gene is very important in keeping a 
healthy structure by modulating the proliferation-differentiation ratio [Lussier et al., 2007].  
The mechanism by which HNF4a helps hold intestinal epithelium homeostasis involves the 
Wnt pathway. When HNF4a is not expressed, increased proliferation in the intestinal crypts is 
observed which suggests that the Wnt pathway is more active than normal [Cattin et al., 2009]. The 
expression of TCF4 is up regulated in the absence of HNF4α, however, when HNF4a gets 
expressed, the β-catenin-TCF4 transcriptional activity is reduced. Furthermore, it has been shown 
(through immuno-precipitation) that HNF4α binds TCF4 and impedes it to associate with β-catenin, 
which results in repression of Wnt genes transcription [Cattin et al., 2009]. 
It is not yet decided if HNF4a acts as an oncogene or a tumour suppressor [Schwartz et al., 
2009]. The reason might be because of the different isoforms HNF4α protein has. HNF4a is 
expressed by two promoter P1 and P2 and their proteins differ in 16 - 29 of their amino acids 
[Bolotin et al., 2010]. It has been shown that P1-HNF4a is missing in 80% of colorectal cancers 
while P2-HNF4α is unaffected [Chellappa et al., 2012]. It has been further shown that HNF4α binds 
to the CDX2 promoter and inhibits its transcription [Boyd et al., 2009]. 
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3.5	  Sp-­‐1	  
The transcription factor specificity protein 1 (Sp-1), encoded by SP1, is involved in the 
regulation of genes essential in early development such as genes that control cell proliferation, 
differentiation, apoptosis, drug resistance, and metastasis [Zhao et al., 2013].  Sp1 contains a zinc 
finger protein motif (Error!	  Reference	  source	  not	  found.) which binds to the consensus sequence 5’-
(G/T)GGGCGG(G/A)G/A)(C/T) - 3’.  Elevated levels of Sp-1 have been found in different kinds of 
tumours, including colorectal cancer tumors, and is associated with patient’s prognosis [Guo et al., 
2010 Campbell et al., 1994]. 
 
3.6	  NF-­‐	  κβ	  
The Nuclear Factor-κβ  (NF-κβ) pathway has been found to be active in all cells, where it is 
involved in regulation of expression of a variety of target genes that are involved in cell 
proliferation, regulate immune and inflammatory response, and contribute to pathogenesis of 
various diseases such as cancer [Wang et al., 2009]. The NF-κβ group of transcription factors 
consist of homodimers or heterodimers of five related proteins: c-Rel, p65 (RelA), RelB, p50 (NF- 
κβ1) and p52 (NF-κβ2) [Gerondakis et al., 2014].  The Rel NF-κβ proteins consist of a conserved 
300 amino acid N-terminal 'Rel homology domain' (RHD) that contains the sequences necessary for 
the  NF-κβ  to bind to consensus DNA motifs (κβ elements), resulting in the formation of dimers. c-
Rel and RelB are associated with active transcription due to their C-terminal transcription 
transactivation domains (TADs) [Gerondakis et al., 2014]. Post-transcriptional processing of 
precursors proteins p105 and p100 results in the formation of p50 and p52, respectively, p50 and 
p52, formed from the N-terminal halves of the precursors, lack a TAD [Gerondakis et al., 2014].  
The NF-κβ pathway is divided into two interacting halves: the classic (also known as 
canonical) and the alternate (nonconical) (figure 4). There is a wide array of stimuli that activate the 
two pathways. The activation that modulates these pathways is controlled by a family of inhibitory 
kappa B kinases (IKKs). The IKKs are made up of three core subunits; the catalytic subunits IKKα 
and IKKβ, and several copies of a regulatory subunit IKKγ (also known as NEMO). The classical 
pathway is activated in response various inflammatory stimuli, including the tumor necrosis factor α 
(TNF-α) cytokine family, interleukin 1β (IL-1β), Toll-like receptor ligands TLRs, or viruses [Wang 
et al., 2009; Gerondakis et al., 2014].  Activation of IKKγ,  IKKβ, and IKKα intermediated kinases 
conveys the signal to the Iκβ phosphorylation.  The phosphorylation results in the degradation of 
the intermediate kinases by the proteasome pathway [Gerondakis et al., 2014].  This pathway 
mostly targets the RelA (p65) heterodimers, which then translocate to the nucleus and activate the 
transcription of various target genes. The activation of this pathway is imperative for immunity and 
responsible for the inhibition of apoptosis under most conditions in response to infections or 
exposure to pro-inflammatory cytokines [Wang et al., 2009]. The alternate pathway plays an 
essential role in the regulation of the development and function of secondary lymphoid organs 
[Wang et al., 2009].  
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Figure	  4:	  The	  classical	  (canonical)	  pathway	  (left)	  and	  the	  alternate	  (noncanonical)	  NF-­‐kβ	  signal	  transduction	  pathway	  can	  be	  seen	  
on	  the	  right	  [Gerondakis	  et	  al.,	  2014]	  	  
 
4. Introduction to Methods 
In this experiment a DNA fragment containing the promoter region of the gene of interest, 
SOX9, was inserted into a promoter vector, pGL4.10. An ideal vector is one that contains sequence, 
that allow them to be replicated autonomously within a host cell and that contains unique cloning 
sites that can be cut by a restriction enzyme to allow site-specific insertion of foreign DNA. In the 
pGL4.10 vector was selected because it contained an ori region, luc2, and a HindIII site. The 
restriction enzyme used was HindIII which cut at the HindIII site. After the vector was linearized, 
the product was purified on a 1% agarose gel containing Ethidium Bromide and TAE Buffer. SOX9 
promoter was amplified using a touch down PCR using the human genome as a template. Fourteen 
PCR reactions were run on a Veriti 96-Well Fast Thermal Cycler. One procedure was a 12 buffer 
system containing 12 buffers with different concentrations of Mg+, while the other contained an HF 
and GC buffer. The PCR product was verified and purified on a 1% agarose gel and using a spin-
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column purification from the “E.Z.N.A Gel Extraction Kit” protocol (Omega Bio-Tek) and the 
correct PCR product cloned into the vector and transformed into competent E.coli, using the 
Invitrogen One Shot ® Mach1™-T1R Chemically Competent E. coli protocol (Invitrogen). The 
growth media, LB agar, was treated with ampicillin because pGL4.10 contains an ampicillin 
resistant gene. The ampicillin resistant bacteria were grown in an overnight LB-media and products 
were purified using a Nucleobond Xtra Maxi Plus Kit (Macherey-Nagel). The purified plasmid was 
cut with HindIII and AvaI restriction enzymes and run on a 1% Agarose gel to ensure that the 
cloning took place. The purified plasmids were then transfected into Caco-2 human cancer cells 
along with transcription factors, overexpression plasmids, and analyzed promoter activity on a 
luciferase assay using the Dual-Light Luciferase and β-Galactosidase Reporter Gene Assay System 
protocol (Applied Biosystems). 
 
5.	  Theory	  of	  Methods	  
5.1	  Primers	  
Primers are prepared oligonucleotides, or short segments of DNA, complementary to 
sequences on opposite strands of the target DNA at positions defining the ends of the segment to be 
amplified [Nelson et al., 2008]. They serve as replication primers that are extended by DNA 
polymerase. Primers allow DNA polymerase to initiate replication and are designed specific to the 
experiment, they are custom built in the lab and can have any sequence of nucleotides. In the 
current experiment Genome UCSC Browser was used to design the primers. In PCR, there are two 
primers, a forward and reverse. Through complementary base pairing, one primer attaches to the top 
strand at one end of your DNA segments of interest and the other primer attaches to the bottom 
strand. Ideally, the two primers will target one place in the entire genome and DNA polymerase will 
attach on and replicate copies of the target sequence [NCBI, 2015]. While designing primers for this 
experiment, it was essential to avoid the coding sequence and start codon of SOX9 due to it possibly 
causing problems in running the Luciferase assay. Having a start codon early in the sequence could 
interfere with the luciferase expression by causing a frameshift mutation. This proved to be difficult 
due to high concentrations of C-G (with stronger bonds than A-T) in the promoter region. After 
many trials, a region of the promoter could be used to design primers for SOX9.  A nonessential 
coding section of the promoter was selected in order design the primer. The length of the primers 
was designed so that they are long enough to be specific and short enough to anneal easily to the 
template during the PCR reaction. The primers used were 20bp for the forward and 18bp for the 
reverse. 
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Figure	  5:	  The	  promoter	  region	  upstream	  SOX9	  gene	  in	  the	  Human	  Genome	  (UCSC	  Genome	  Browser)	  
Table	  1:	  Forward	  and	  Reverse	  Primers	  
OLIGO	   Tm	  
(Cᴼ)	  
GC%	   Primer	  Sequence	  
5'	  -­‐>	  3'	  
In-­‐fusion	  Primer	  Sequence	  	  
5'	  -­‐>	  3'	  
Resulting	  
Fragment	  length	  	  
Forward	  
Primer	  
	  
60.2
8	  
50.0
0	  
CGTAAACTCGGCTACGC
ATT	  
CTCGGCGGCCAAGCTTCGTAAACT
CGGCTACGCATT	  
703	  bp	  
Reverse	  
Primer	  
59.6
9	  
61.1
1	  
CGGCGAGCACTTAGGA
AG	  
CCGGATTGCCAAGCTTCGGCGAGC
ACTTAGGAAG	  
Using the Clontech In-Fusion PCR Cloning System design program (Clontech) In-Fusion 
Primers were designed containing a HindIII restriction site, reserving the restriction site. The 
infusion tags add on extra nucleotides to the forward and reverse primers. The extra nucleotides are 
complementary to the nucleotides surrounding the HindIII site in the pGL4.10 promoter and they 
contain a HindIII restriction site. This is necessary for specificity. Once the promoter PCR product 
was added with the InFusion Tags in each end, to the lintera pGL4.10 vector with the t3 ligase, the 
ligase used the InFusion tags on the PCR product to ligate it into the pGL4.10 vector. The InFusion 
tags were designed to be used as “guides” for the promoter fragment into the correct position of the 
pGL4.10 vector.   
 
 
Figure	  6:	  Infusion	  Tag	  forward	  and	  reverse	  primers	  (Clontech).	  
 
5.2	  Polymerase	  Chain	  Reaction	  
Polymerase Chain Reaction (PCR) is PCR is a technique that amplifies a specific fragment of 
DNA containing a target gene of interest and inserting it into a cloning vector. The cloning vector used 
was pGl4.10 and for the experiment, the promoter region of the SOX9 gene was amplified. During the 
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reaction, the mixture containing the DNA template, DNA polymerase, and nucleotides is heated to 
unwind the DNA breaking the hydrogen bonds between nucleotides, resulting in single stranded DNA. 
The mixture is cooled to allowing the forward and reverse primers to anneal to the start and end of the 
target sequence on the 3´ends [Nelson et al., 2008].The PCR mixture is then heated again to 72 degrees 
Celsius which is the ideal temperature for DNA polymerase to attach primers and to synthesize new 
complementary DNA strands DNA polymerase adds the free nucleotides through base pairing to the 
single stranded DNA and begins DNA synthesis [Berg et al., 2002]. The process continues until 
there are two full copies of the target DNA.  The new mixture is put through the steps again, the 
PCR steps are repeated 30 times until the PCR has reached its limit and the target DNA is 
amplified. 
In the current study, a Touchdown PCR was run. Touchdown PCR was chosen because in 
normal PCR, a frequent problem occurs in PCR amplification of target gene sequences [Don et al., 
1991]. The problem is the appearance of specious smaller bands in the product spectrum and it is 
due to mispriming by either or both of the primers internal or external to the target template [Don et 
al., 1991].  Adjustments to the Mg+ or increasing the annealing temperature of the PCR may solve 
this problem, and therefore Touchdown PCR was chosen. In Touchdown PCR, the primers avoid 
amplifying nonspecific sequences. The exponential nature of PCR reactions are taken advantage of 
in touchdown PCR, in the Veriti touch down PCR, the annealing temperature is lowered 1 °C every 
cycle. The annealing temperature starts at 68°C to a touch down at 58°C, at which 10 cycles are 
carried out. Then an additional 30 cycles were carried out at 58 °C for amplification.  
	  
	  
  
Figure	   7:	   Polymerase	  Chain	  Reaction	   (PCR)	   steps.	   Touch	  down	   steps	   (right)	   are	   extra	   steps	   in	   step	   2,	   annealing	   temperature.	  
[Wikimedia,	  2015]	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5.2.1	  DNA	  Polymerase	  
DNA polymerase is the enzyme responsible for copying DNA before the cell divides into 
two. The DNA polymerase will attach onto the primer through base pairing with a longer pieces of 
DNA. DNA polymerase attaches close to the end of the primer and starts adding nucleotides. DNA 
polymerases that are naturally occurring in the human body will denature at temperatures much 
lower than 95 degrees Celsius, the temperature necessary to separate two complementary strands of 
DNA in a test tube. The DNA polymerases used in PCR are specially chosen from heat resistant 
bacteria. These polymerases can withstand much higher temperatures as the bacteria live in hot 
springs [NCBI, 2015].   
	  
5.4.2	  DNA	  Template	  
The DNA template is the sample that contains the target sequence. At the beginning of the 
reaction, high temperature is applied to the original-stranded DNA molecule to separate the two 
strands.         
5.4.3	  Nucleotides	  
Nucleotides are the building blocks of DNA molecules. In PCR, a mixture of adenine, 
guanine, thymine, and cytosine will be added to the PCR reaction. The DNA polymerase latches on 
to nucleotides in the mixture and attaches them to the ends of the primers.    
	  
5.4.4	  Limits	  of	  the	  PCR	  
Because of inhibitors of the polymerase reaction found in the sample, reagent limitation, 
accumulation of pyrophosphate molecules, and self-annealing of the accumulation product, the PCR 
reaction eventually ceases to amplify the target sequence at an exponential rate and a plateau effect 
occurs, making the end point quantification of PCR products unreliable [NCBI, 2015].   
 
5.3	  Gel	  electrophoresis	  
Gel electrophoresis is the technique of separating strands of DNA based off size of 
fragments. The technique can be used to confirm a PCR product. A 1% agarose gel was made and 
placed in a Tris-Acetate-EDTA (TAE) Buffer, a salt buffer that can conduct electricity when 
hooked up to electrodes. Ethidium bromide (EtBr) is added to the gel to identify the DNA bands 
under UV light. Ladders are used a reference, a scale of base pair sizes and there is a reference for 
all ladders so that the results can be identified by size. The ladder is inserted to the first well, then, 
the samples are loaded, one or more containing the target DNA and a DNA reference to compare to 
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the target DNA. The voltage is adjusted accordingly. Once the electrodes are turned on, the 
negatively charged phosphates will cause the samples to travel towards the positively charged end 
of the gel, leaving stripes along the gel. The ladder is used to identify the size of the DNA and 
identify if the number of base pairs matches the size of the desired DNA fragment. Shorter strands 
of DNA tend to travel further on the gel than longer strands but this is not always the case. 
Sometimes longer pieces of DNA will travel further if they are more compact than the desired DNA 
sample. 
  
5.3.1	  Agarose	  gel	  
Agar is a complex mixture of polysaccharides, all with the same backbone structure, but 
substituted to varying degrees with sulfate and pyruvate. Agarose is the agar component with the 
fewest charged groups (sulfates, pyruvates). When a suspension of agarose in water is heated and 
cooled it forms a double helix gel form. The gel-forming property makes it useful in electrophoretic 
separation of nucleic acids, in the biochemistry laboratory [Nelson et al., 2008]. The distance 
between DNA bands of different lengths is influenced by the percent of agarose in the gel. Higher 
percentages of agarose require longer experiments, which require other types of electrophoresis 
methods to keep the experiments shorter. 
	  
5.3.2	  Ethidium	  Bromide	  
Ethidium Bromide (EtBr) is used to detect nucleic acids, usually from PCR products. It is 
added to a running buffer during the separation of DNA fragments in agarose gel electrophoresis. 
Upon binding to the DNA molecule and lamination with UV light source, the DNA banding pattern 
becomes visible [Sigmon et al., 1996]. 
 
Figure	  8:	  Ethidium	  Bromide.	  When	  exposed	  to	  UV	  light,	  EtBr	  emits	  yellow-­‐orange	  visible	  light,	  allowing	  for	  easy	  identification	  of	  
DNA	  bands	  [Thermo	  Fisher	  Scientific	  Inc.,	  2015,	  image	  source:	  Wikimedia,	  2006]	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5.4	  pGL4.10	  
The pGL4.10 [luc2] is a commercially-available reporter vector from Promega (EE6651) 
that lacks a promoter of its own, but contains the sequence for a modified luc2 gene, a firefly 
luciferase, as well as ampR, a gene that provides resistance to ampicillin antibiotics. ampR functions 
as a selective marker; after transformation of the plasmid into E. coli, all cells that have not 
integrated the plasmid will be killed by addition of ampicillin. The modifications to the luc2 gene 
improve expression levels in mammalian cells and prevent cryptic transcription – that is, 
unintentional transcription of mRNA molecules that are immediately degraded by the cell [Neil et 
al., 2009]. By taking the promoter region from a gene of interest - SOX9 in human genome DNA, in 
the case of this experiment - and inserting them into the pGL4.10 vector, a complete, functional 
plasmid is created. When the DNA of the plasmid is integrated into a Caco-2 cell, activation of the 
SOX9 promoter will lead to the synthesis of luciferase. 
 	  
Figure	  9:	  The	  figure	  shows	  the	  plasmid,	  PGL4.10	  [luc2]	  with	  the	  SOX9	  promoter	  fragment.	  The	  plasmid	  contains	  the	  firefly	  
luciferase	  2	  gene,	  a	  synthetic	  beta-­‐lactamase	  gene,	  and	  genes	  to	  confer	  ampicillin	  resistance.	  Binding	  sites	  for	  restriction	  sites	  for	  
restriction	  enzymes	  used	  in	  our	  experiment	  (HindIII,	  AvaI)	  are	  also	  highlighted.	  	  Image	  created	  with	  Unipro	  UGENE.	  
	  
5.5	  Transformation	  to	  E.	  coli	  
With the methods of PCR and cloning, virtually any gene can be purified. The essence of 
recombinant DNA technology is the preparation of large numbers of identical DNA molecules. A 
DNA fragment of interest is linked through strand 3´→5´phosphodiester bonds to a vector DNA 
molecule, which can replicate when introduced into a host cell. When single recombinant DNA 
molecules, composed of a vector plus an inserted DNA fragment, are introduced to a host cell, the 
inserted DNA is reproduced along with the vector, resulting in large amounts of recombinant DNA 
molecules that include the target fragment linked to the vector. E. coli plasmid vectors and 
bacteriophages are the most common vectors [Lodish et al., 2008]. Most plasmid vectors contain 
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little more than the essential nucleotide sequences for their use in DNA cloning: a replication origin, 
a drug-resistance gene, and region where exogenous DNA fragments can be inserted. 
	  
	  
 
Figure	  10:	  Transformation	  of	  plasmid	  with	  component	  E.coli	  bacteria 	  
	  
5.6	  Plasmid	  DNA	  Replication	  
The replication origin (ORI) is a specific DNA sequence 50-100 base pairs that must be 
present in a plasmid for replication. Host-cell enzymes bind to ORI, initiating replication of the 
circular plasmid. Once initiation takes place, it continues around the circular plasmid, therefore, any 
DNA sequence inserted in the plasmid will be replicated and incorporated into the DNA [Lodish et 
al., 2008].   
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5.7	  Caco-­‐2	  Cells	  
The Caco-2 cells are human heterogeneous epithelial colorectal cancer cells. They are 
originally from a colon carcinoma. When Caco-2 cells are cultured under specific conditions, they 
end up adopting the characteristics of the enterocytes lining the small intestine. The cells become 
differentiated and polarized so that their phenotype, morphology and functional abilities simply 
morph and change. Caco-2 cells express microvilli, and a number of enzymes and transporters that 
are characteristic of such enterocytes; peptidases, esterases, P-glycoprotein, uptake transporters for 
amino acids, bile acids carboxylic acids. Caco-2 cancer cells are commercially available [Ebrahimi 
et al.,2014]. 
Caco-2 cells are used as a confluent monolayer on a cell culture filter. When cultured in this 
format, the cells differentiate to form a polarized epithelial cell monolayer that provides a physical 
and biochemical barrier to the passage of ions and small molecules [Artursson et al., 1990]. The 
Caco-2 monolayer is widely used across the pharmaceutical industry as an in vitro model of the 
human small intestinal mucosa to predict the absorption of orally administered drugs. 
Caco-2, human colon cancer cells, were grown in VWR Tissue Culture Flasks (VWR 
International) at 37°C and 5% CO2. Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza) 
treated with 100 µg/ml streptomycin, 100 U/ml penicillin, and 10% foetal calf serum was used as 
growth media. Cell cultures were washed with 85mM sodium citrate (Sigma Aldrich) to remove 
media, trypsinized (Gibco), and seeded into culture flasks when 70-90% confluent to prevent 
differentiation. Confluence was estimated by observation with a light microscope. 
	  
5.8	  Transfection	  	  
Transfection, introduction of DNA to eukaryotic cells, of the plasmid DNA into the Caco-2 
cells is accomplished with the use of polyethylenimine, PEI. PEI carries the plasmid DNA and is 
taken into the Caco-2 cell via endocytosis [Boussif et al., 1995]. The pGL 4.10 plasmid and lacZ 
plasmid, necessary for the dual-light assay, are mixed with PEI. The mixture is incubated for 1-2 
hours and then added to Caco-2 cells, after which the cells are spun and incubated. The transfection 
was performed according to the following schemes: 
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Table	  2	  and	  Table	  3	  show	  the	  scheme	  used	  for	  transfection	  of	  transcription	  factors	  into	  the	  cells.	  The	  final	  volume	  of	  all	  mixes	  is	  
100	  µg,	  to	  which	  4	  µl	  of	  PEI	  are	  added.	  Table	  2	  contains	  the	  scheme	  for	  the	  1:3	  clones	  and	  Table	  3	  contains	  the	  scheme	  for	  the	  
1:4	  clones	  
	  Table	  2:	  
	  
	  
	  
	  
Table	  3:	  shows	  the	  mixture	  scheme	  for	  the	  1:4	  clones.	  The	  final	  volume	  of	  all	  mixes	  is	  100	  µg,	  to	  which	  4	  µl	  of	  PEI	  are	  added.	  
	  
DNA	  in	  µg	  for	  
4	  replicates
pGL4.10	  
SOX9	  (2.4	  
ng/µl)
CMV-­‐lacZ	  
(15.2	  ng/µl)
TCF4	  (81.8	  
ng/µl)
CDX2	  (1820	  
ng/µl)
p65	  (4.1	  
ng/µl)
p50	  (3.9	  
ng/µl)
p52	  
(1.1ng/µl)
SP-­‐1	  (10.0	  
ng/µl)
c-­‐jun	  (10	  
ng/µl)
c-­‐fos	  
(10ng/µl)
SOX9	  
(70ng/µl)
HNF4-­‐α	  
(5.0ng/µl)
pcDNA	  3.1	  +	  
(21.8ng/µl)
pSK+	  
(26.4ng/µl)
NaCl	  (150	  
mM)
pGL4.10	  
SOX9	  (2.8	  
ng/µl)
6.9 6.6 7.6 26.5 52.4
pGL4.10	  
SOX9	  +	  TCF4
6.9 6.6 1.4 3.8 26.5 54.8
pGL4.10	  
SOX9	  +	  CDX2
6.9 6.6 1.2 3.8 26.5 55
pGL4.10	  
SOX9	  +	  	  p65	  
+	  p50
6.9 6.6 10 3.8 26.5 46.2
pGL4.10	  
SOX9	  +	  p65	  	  
+	  p52
6.9 6.6 5.5 3.8 26.5 50.7
pGL4.10	  
SOX9	  +	  SP1
6.9 6.6 2 2.5 0 26.5 55.4
pGL4.10	  
SOX9	  +	  c-­‐jun	  
+	  c-­‐fos
6.9 6.6 2 9.1 0 26.5 48.9
pGL4.10	  
SOX9	  +	  SOX9
6.9 6.6 10 10 0 26.5 40
pGL4.10	  
SOX9	  +	  CDX2	  
+	  HNF4-­‐α
6.9 6.6 5.5 0 26.5 52.5
pGL4.10	  
SOX9	  +	  HNF4-­‐
α
6.9 6.6 5.5 10 2 0 26.5 44.5
pGL4.10 8.4 6.6 7.6 26.5 50.9
Transfected	  
with	  GFP	  
plasmid
25 0 0 75
DNA	  in	  µg	  for	  
4	  replicates
pGL4.10	  
SOX9	  (2.4	  
ng/µl)
CMV-­‐lacZ	  
(15.2	  ng/µl)
TCF4	  (81.8	  
ng/µl)
CDX2	  (1820	  
ng/µl)
p65	  (4.1	  
ng/µl)
p50	  (3.9	  
ng/µl)
p52	  
(1.1ng/µl)
SP-­‐1	  (10.0	  
ng/µl)
c-­‐jun	  (10	  
ng/µl)
c-­‐fos	  
(10ng/µl)
SOX9	  
(70ng/µl)
HNF4-­‐α	  
(5.0ng/µl)
pcDNA	  3.1	  +	  
(21.8ng/µl)
pSK+	  
(26.4ng/µl)
NaCl	  (150	  
mM)
pGL4.10	  
SOX9	  (2.8	  
ng/µl)
6.5 6.6 7.6 26.5 52.9
pGL4.10	  
SOX9	  +	  TCF4
6.5 6.6 1.4 3.8 26.5 55.2
pGL4.10	  
SOX9	  +	  CDX2
6.5 6.6 1.2 3.8 26.5 55.4
pGL4.10	  
SOX9	  +	  	  p65	  
+	  p50
6.5 6.6 10 3.8 26.5 46.7
pGL4.10	  
SOX9	  +	  p65	  	  
+	  p52
6.5 6.6 5.5 3.8 26.5 51.2
pGL4.10	  
SOX9	  +	  SP1
6.5 6.6 2 2.5 0 26.5 55.9
pGL4.10	  
SOX9	  +	  c-­‐jun	  
+	  c-­‐fos
6.5 6.6 2 9.1 0 26.5 49.3
pGL4.10	  
SOX9	  +	  SOX9
6.5 6.6 10 10 0 26.5 40.4
pGL4.10	  
SOX9	  +	  CDX2	  
+	  HNF4-­‐α
6.5 6.6 5.5 0 26.5 53
pGL4.10	  
SOX9	  +	  HNF4-­‐
α
6.5 6.6 5.5 10 2 0 26.5 45
pGL4.10 8.4 6.6 7.6 26.5 50.9
Transfected	  
with	  GFP	  
plasmid
25 0 0 75
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5.9	  Luciferase	  Assay	  
Luciferases are a class of enzymes found in many species that create bioluminescent 
reactions. Adding luciferase to the cell provides a way to measure expression levels of the SOX9 
promoter quantitatively. Expression of SOX9 produces luciferase, which can be measured by 
fluorescence assays. The luc2 gene in pGL4.10 [luc2] originates from the common eastern firefly, 
Photinus pyralis. Luc2 luciferase uses D-luciferin as its substrate, along with MgATP and 
molecular oxygen, O2, as cofactors. Luciferase oxidizes D-luciferin to oxyluciferin. The 
oxyluciferin is in an electronically excited state upon formation. The reaction is completed when the 
excited oxyluciferin releases a photon and returns to the ground state (Klementyeva et al., 2013). 
A Dual-Light ® System (Applied Biosystems) assay was used to measure the effects of the 
different transcription factors on SOX9 promoter expression. The assay measures the amounts of two 
different enzymes, luciferase and β-galactosidase, in the lysate of cells. Luciferase is not an enzyme 
normally produced in mammalian cells, and is introduced into the cell’s DNA with the pGL 4.10 [luc2] 
plasmid. β-galactosidase is expressed constitutively, and β-galactosidase measurements are used to 
normalize luciferase measurements across different samples. 
Substrate for each enzyme is added to the lysate. The subsequent reactions produce light, which 
is measured with a luminometer. The luciferase and β-galactosidase reactions occur at different pHs, so 
buffers are used to ensure that only one type of reaction occurs at a time [Martin et al., 1996]. 
 
Figure	  11:	  Schematic	  of	  Luciferase	  Reporter	  Assay	  [Life	  Technologies,	  2015]	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5.10	  Limitation	  of	  Luciferase	  Assay	  
A luciferase assay reveals how often the promoter of the gene of interest is activated and 
makes it easy to detect differences that occur when different variables (e.g. transcription factors) are 
introduced to the cell. The luciferase assay is not, however, able to show all of the interactions that 
occur between the various transcription factors, signalling pathways, and DNA that produce the 
differences. As a result, the exact nature of the changes brought about by the introduction of a 
transcription factor can only be guessed at. 
 
6.	  Sequence	  data	  
 
Figure	  12:	  Sequence	  alignment	  of	  1:3	  clone	  with	  the	  SOX9	  promoter	  
 
Figure	  13:	  Sequence	  alignment	  of	  1:4	  clone	  with	  the	  SOX9	  promoter	  
Figure	  14:	  Sequence	  1:3	  clone	  forward	  strand	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Figure	  15:	  Sequence	  1:4	  clone	  forward	  strand	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